Summit Therapeutics PLC Sponsored ADR Stock News

Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript

Summit Therapeutics plans to file for a key FDA approval by the end of this year. The drugmaker is betting that the FDA will change its mind on guidance already handed down.

Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

SoFi Technologies could become the dominant banking model in the future. Summit Therapeutics is developing a drug with incredible sales potential.

I'm rating Summit Therapeutics a 'cautious Buy' based on the promising dual-action lung cancer therapy Ivonescimab and significant insider buying. SMMT's Ivonescimab targets non-small cell lung cancer through its dual Anti-PD-1 plus Anti-VEGF mechanism, with the potential to outperform the benchmarks. While there's a lot of uncertainty regarding sales and even more to earnings, valuation sugges...

Summit Therapeutics Inc. ( SMMT ) Jefferies London Healthcare Conference 2025 November 18, 2025 10:30 AM EST Company Participants Dave Gancarz - Chief Business & Strategy Officer Manmeet Soni - COO, CFO & Director Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Clara Dong Presentation Yuxi Dong Jefferies LLC, Research Division All right. Good afternoon.

Summit Therapeutics Inc. ( SMMT ) UBS Global Healthcare Conference 2025 November 10, 2025 3:30 PM EST Company Participants Dave Gancarz - Chief Business & Strategy Officer Manmeet Soni - COO, CFO & Director Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division All right, everyone. Thank you for joini...

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK) published results from the Phase III HARMONi-A trial, conducted in China and sponsored by Akeso, featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented ...